Track topics on Twitter Track topics that are important to you
President Donald J. Trump recently signed the FDA Reauthorization Act of 2017 into law. The FDA Reauthorization Act of 2017 (H.R. 2430) reauthorizes the user fee programs for prescription drugs, medical devices, generic drugs and biosimilars, and amends FDA authorities and activities related to medical products. The user fees, which are paid by manufacturers of drugs and medical devices, account for $8 billion to $9 billion during a period of 5 years. The law includes the Generic Drug User Fee Amendments, the Biosimilar User Fee Act, the Prescription Drug User Fee Act and the Medical Device User Fee Amendments, which must be reauthorized by Sept. 30.
Original Article: Trump signs FDA Reauthorization Act of 2017 into lawNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...